More serious adverse effects include pancreatitis, gallbladder disease, hypoglycemia (especially when used with insulin or sulfonylureas), acute kidney injury from dehydration, and hypersensitivity reactions
Pharm Res (2022) 39(6):123348
Although GLP-1 medications have been around for decades as diabetes drugs, they have only recently been approved for weight loss by the Federal Drug Administration (FDA), and thats what has led to a significant increase in popularity and a rise in microdosing them
While addressing a particular skin condition might not happen immediately, other favorable improvements will manifest sooner
A critical understanding of these interrelationships is essential for formulating optimized diets that maximize animal health, productivity, and final product quality
Therefore, GLP-1R agonists may be new and promising treatment alternatives for obese subjects